Trial Profile

A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olipudase alfa (Primary)
Indications Niemann-Pick disease type B
Focus Adverse reactions
Sponsors Sanofi; Sanofi Genzyme

Most Recent Events

14 Nov 2023 Results assessing liver and lipid values at baseline and after 2years of olipudase alfa treatment in ongoing clinical trials and extensions (NCT02004691, NCT02292654 NCT02004704, NCT01722526) and phase 1b trial presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
22 Sep 2023 Status changed from active, no longer recruiting to completed.
10 Aug 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com